glp-1 receptor agonist mechanism of action Trends in the Development Agonists Frontiers | Exploring the multifaceted

Furthermore, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths (46)

protects heart health

49,55,56,67 However, most of the clinical studies conducted up to date have focused on evaluating the effects of small molecule oral GLP-1 RAs against placebo

In addition to aforementioned properties of GLP-1 agonists, it can also reduce hypertension by activating and phosphorylating endothelial nitric oxide synthase pathways, thus increasing the bioavailability of nitric oxide which promotes vasodilation

This slows down the rate at which glucose enters your bloodstream, which helps keep your blood sugar level steady